Can I get it?
Yes, if a doctor decides it is right for you. Finerenone is authorised in the EU and can be prescribed after a medical review.
Finerenone · Vienna
Finerenone in Vienna.
Not in our consultation yet. We are continuously onboarding new specialists — leave your email and we'll notify you, or explore the areas we already cover, skin included.
NOTIFY ME WHEN AVAILABLE
Leave your email and we'll notify you when we add Finerenone.
NOT AVAILABLE TODAY
Hi-Doctor does not prescribe Finerenone yet.
Our licensed doctors currently cover hair growth, weight management, sexual health and skin — acne, rosacea, melasma and ageing skin. We extend the catalogue as specialists join and regulation allows. Finerenone is outside it today.
Buying Finerenone online without a valid prescription carries counterfeiting and toxicity risks. Always consult a licensed healthcare professional.
IN PLAIN TERMS
What Finerenone is, and how to get treatment
Finerenone, sold as Kerendia, is a kidney and heart medicine. It calms an overactive hormone signal that drives scarring in the kidney, and it holds an EU-wide marketing authorisation for chronic kidney disease with albuminuria in adults who also have type 2 diabetes. It is a specialist medicine: it needs regular blood-potassium checks and is normally started by a kidney or diabetes doctor. Hi-Doctor covers hair loss, weight management, sexual health and skin, and does not treat kidney disease or diabetes.
Finerenone has been authorised for use in the EU since 16 February 2022, so a licensed doctor can prescribe it when it is clinically appropriate for you.
What can I take instead?
Our doctors review every option and recommend what fits your history and goals.
What do the studies show?
Every trial behind Finerenone is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.
Jump to the studiesWHAT WE DO COVER
If your question is about hair, weight, sexual health or skin, a licensed doctor reviews it in less than 2 hours on average — €35, or €40 for a skin consultation.
TREATMENTS
Different needs, one process.
Choose what fits. The journey is identical.
Licensed EU doctors
Doctor review in less than 2 hours on average
50,000+ patients served
Secure patient account
VERIFIED EVIDENCE
Finerenone: evidence and regulatory guide.
WHAT IT IS
How it works
Blocks the mineralocorticoid receptor, a signal in the kidney and heart that drives inflammation and scarring when it is overactivated.
- mineralocorticoid receptor
DEVELOPMENT STAGE
EU-authorised medicine
Trial register1 registered trials
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| FIDELIO-DKDNCT02540993 | Adults with chronic kidney disease and type 2 diabetes already treated with a renin-angiotensin system blocker | 5,734 | Read out | 2020-10-23 |
What the studies reported
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
Peer-reviewed
Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| 10–20 mg once daily | Primary kidney composite outcome 17.8% vs 21.1% on placebo over a median 2.6 years (hazard ratio 0.82, 95% CI 0.73–0.93; P=0.001) | — |
| 10–20 mg once daily | Key secondary cardiovascular composite outcome 13.0% vs 14.8% on placebo (hazard ratio 0.86, 95% CI 0.75–0.99; P=0.03) | — |
Everyone enrolled had both chronic kidney disease with albuminuria and type 2 diabetes, and was already on a renin-angiotensin blocker; the trial says nothing about people without those conditions.
Sources
Last reviewed 2026-07-27
NAMED SAFETY SIGNALS
What has been reported with Finerenone.
High blood potassium (hyperkalaemia)
The most frequently reported side effect, affecting more than 1 in 10 people. In FIDELIO-DKD investigator-reported hyperkalaemia occurred in 18.3% on finerenone vs 9.0% on placebo, and 2.3% of the finerenone group stopped treatment because of it. Blood potassium must be monitored.
Other common effects
Low blood sodium, raised uric acid, low blood pressure, itching and reduced kidney function each reported in up to 1 in 10 people.
Contraindications and interactions
Must not be used in Addison's disease, or together with medicines that strongly inhibit the liver enzyme CYP3A4.
HOW IT WORKS · 5 STEPS
Five steps. No waiting room.
From the online consultation to ongoing follow-up — without leaving home.
- 5 minutes
Start your online visit
Answer a 5-minute health questionnaire from home.
- Less than 2 hours
A doctor reviews your case
A licensed doctor reviews your answers and replies personally.
- Refund guarantee
Review and payment
If not approved, we refund your €35 one-off in full.
- EU pharmacies
Collect treatment from the pharmacy
Collect it at any EU pharmacy with your e-prescription.
- 4-week check-in
Ongoing support
Private chat, 4-week check-in, simple prescription renewal.
NOTIFY ME
Leave your email and we'll notify you when Finerenone becomes available.
We only use your email for this notification. You can opt out at any time.
FREQUENTLY ASKED QUESTIONS